Eckert & Ziegler SE (ETR:EUZ)
Germany
· Delayed Price · Currency is EUR | Market Cap | 944.87M |
| Revenue (ttm) | 311.96M |
| Net Income (ttm) | 48.76M |
| Shares Out | 62.57M |
| EPS (ttm) | 0.78 |
| PE Ratio | 19.37 |
| Forward PE | 18.10 |
| Dividend | 0.22 (1.46%) |
| Ex-Dividend Date | Jun 19, 2025 |
| Volume | 153,188 |
| Average Volume | 127,001 |
| Open | 15.17 |
| Previous Close | 15.06 |
| Day's Range | 14.80 - 15.27 |
| 52-Week Range | 13.30 - 23.25 |
| Beta | 1.54 |
| RSI | 51.95 |
| Earnings Date | May 12, 2026 |
About Eckert & Ziegler SE
Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds based on iodine-125; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of choroidal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceu... [Read more]
Financial Performance
In 2025, Eckert & Ziegler SE's revenue was 311.96 million, an increase of 5.45% compared to the previous year's 295.85 million. Earnings were 48.76 million, an increase of 46.54%.
Financial StatementsNews
EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Eckert & Ziegler SE Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide di...
Q4 2025 Eckert & Ziegler SE Earnings Call Transcript
Q4 2025 Eckert & Ziegler SE Earnings Call Transcript
Eckert & Ziegler SE Earnings Call Transcript: Q4 2025
Revenue and EBIT adjusted grew strongly in 2025, driven by medical segment expansion and new market entries. 2026 guidance anticipates continued growth, with high CapEx for global facility expansion and normalization in oil well logging.
EQS-DD: Eckert & Ziegler SE: Dr. Gunnar Mann, Allocation of 12,545 shares as part of executive board remuneration (own shares of the issuer). This is a share-based remuneration with an automatic ...
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 24.03.2026 / 10:17 CET/CEST The issuer is solely responsi...
EQS-DD: Eckert & Ziegler SE: Dr. Harald Hasselmann, Allocation of 62,541 shares as part of executive board remuneration (own shares of the issuer). This is a share-based remuneration with an ...
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 24.03.2026 / 10:04 CET/CEST The issuer is solely responsi...
EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Eckert & Ziegler SE Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide di...
EQS-Adhoc: Eckert & Ziegler Plans Dividend of € 0.22 per Share for 2025
EQS-Ad-hoc: Eckert & Ziegler SE / Key word(s): Dividend payments Eckert & Ziegler Plans Dividend of € 0.22 per Share for 2025 06-March-2026 / 10:36 CET/CEST Disclosure of an inside information acc. to...
EQS-AFR: Eckert & Ziegler SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQS Preliminary announcement financial reports: Eckert & Ziegler SE / Preliminary announcement on the disclosure of financial statements Eckert & Ziegler SE: Preliminary announcement of the publicatio...
EQS-AFR: Eckert & Ziegler SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Eckert & Ziegler SE / Preliminary announcement on the disclosure of financial statements Eckert & Ziegler SE: Preliminary announcement of the publicatio...
Original-Research: Eckert & Ziegler SE (von NuWays AG): BUY • news
Eckert & Ziegler SE at JPMorgan Healthcare Conference Transcript
Eckert & Ziegler SE at JPMorgan Healthcare Conference Transcript
Eckert & Ziegler SE Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company is expanding its global footprint and investing in capacity to meet rising demand for radioligand therapies, with strong growth in the medical segment and a robust financial position. Strategic partnerships, CDMO expansion, and selective M&A are key to future growth.
EQS-News: Reorganization of the Eckert & Ziegler Executive Board
EQS-News: Eckert & Ziegler SE / Key word(s): Personnel Reorganization of the Eckert & Ziegler Executive Board 05.12.2025 / 16:10 CET/CEST The issuer is solely responsible for the content of this annou...
EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Eckert & Ziegler SE Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide di...
Eckert & Ziegler To Supply SK Biopharmaceuticals With Actinium-225 To Boost Research, Development
SEOUL (dpa-AFX) - Eckert & Ziegler AG (EUZ.F, EUZ.DE), a German isotope technology components firm, said on Wednesday that it has agreed to supply Actinium-225, or Ac-225, to SK Biopharmaceuticals...
Eckert & Ziegler SE Transcript: German Equity Forum 2025
The company is experiencing strong growth in radiopharmaceuticals, driven by market leadership in gallium generators and expanding global demand, especially in North America and China. Financial performance remains robust, with double-digit growth in the Medical segment and new facilities supporting future expansion.
Eckert & Ziegler SE Earnings Call Transcript: Q3 2025
Revenue grew 4% and adjusted EBIT 9% year-over-year, led by strong medical segment performance and recovery from early-year disruptions. Guidance for €320 million sales and €78 million EBIT remains, contingent on Q4 license income. Asia, especially China and Japan, is a key growth driver.
EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Eckert & Ziegler SE Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide di...
EQS-News: Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation and a Price Target of € 24 – Price Potential 47%
EQS-News: Eckert & Ziegler SE / Key word(s): Research Update Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation and a Price Target of € 24 – Price Potential 47% 09.09.2025 / 11:30...
Eckert & Ziegler SE Earnings Call Transcript: Q2 2025
H1 2025 saw modest sales growth and improved profitability, led by the medical segment, while industry isotope sales declined. Full-year guidance is reaffirmed, with expectations for stronger H2 performance from license deals and segment recovery.
Eckert & Ziegler Earnings Surge in Early 2025
Eckert & Ziegler SE, a leader in isotope technology, reports strong financial results for early 2025, signaling continued growth and stability in the radiopharmaceutical sector. Jetzt den vollständige...
EQS-News: Eckert & Ziegler: Further Increase in Earnings in the First Half of 2025
EQS-News: Eckert & Ziegler SE / Key word(s): Half Year Results/Half Year Report Eckert & Ziegler: Further Increase in Earnings in the First Half of 2025 08.08.2025 / 07:45 CET/CEST The issuer is solel...
EQS-News: Eckert & Ziegler: Implementation of the Share Split by Issuing Bonus Shares to Be Effective on 15 August 2025
EQS-News: Eckert & Ziegler SE / Key word(s): Corporate Action Eckert & Ziegler: Implementation of the Share Split by Issuing Bonus Shares to Be Effective on 15 August 2025 05.08.2025 / 11:50 CET/CEST ...
EQS-News: Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101
EQS-News: Eckert & Ziegler SE / Key word(s): Incoming Orders/Agreement Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101 29.07.2025 / 14:00 CET/CEST...
EQS-News: Eckert & Ziegler: Capital Increase Entered in the Commercial Register. Share Split in Preparation.
EQS-News: Eckert & Ziegler SE / Key word(s): Corporate Action Eckert & Ziegler: Capital Increase Entered in the Commercial Register. Share Split in Preparation. 28.07.2025 / 14:30 CET/CEST The issuer ...